Recent developments include clinical trial progress, regulatory designations, financing activities, and management appointments.

• Azitra dosed the first patient in its ATR-12 Phase 1b/2a clinical trial for Netherton syndrome in August 2024 and reported initial safety results in the first half of 2025 [S1].
• The ATR-04 program received FDA Fast Track designation in September 2024 and dosed its first patient in a Phase 1/2 trial in Q3 2025 [S1][N4].
• Azitra completed a private placement in March 2026 to advance new cosmetic protein and peptide programs [N2].
• The company received NYSE American listing compliance notices in October 2025 and March 2026 and is operating under a compliance plan through April 2027 [N3][S2].
• Azitra priced an underwritten public offering of 16.67 million shares at $0.30 per share in February 2024 [N6].
• Travis Whitfill was named Chief Operating Officer in July 2023 [N7].

Azitra’s innovative approach to precision dermatology leverages a large proprietary microbial library and advanced AI technologies to identify and engineer therapeutic proteins and peptides. The company’s lead candidates have progressed into early clinical trials, with ATR-04 receiving FDA Fast Track designation, indicating regulatory recognition of its potential. Exclusive licensing of SyMPL technology may enable engineering of a broader range of bacterial strains, expanding the pipeline. Strategic partnerships with top academic institutions provide access to cutting-edge research and technology. Recent financing activities support ongoing development of new cosmetic protein and peptide programs, potentially broadening the company’s product portfolio.

Azitra is an early-stage clinical company with no commercial products or revenue to date, relying on successful clinical development and regulatory approvals to advance its pipeline. The company reported net losses and limited cash reserves as of mid-2026, which may constrain operations without additional financing. Compliance issues with NYSE American listing standards pose risks to market liquidity and capital access. The complexity of genetically engineering bacteria and delivering therapeutic proteins through the skin barrier presents scientific and regulatory challenges. Market acceptance of live biotherapeutic products and competition from established dermatology and biotech companies add to execution risks.

Azitra’s moat is based on its proprietary microbial library of over 1,500 unique bacterial strains, including a large collection of genetically diverse Staphylococcus epidermidis strains, and its AI-driven platform for identifying therapeutic proteins and peptides. The company’s exclusive license to Fred Hutch’s SyMPL technology enables genetic engineering of previously intractable bacterial strains, potentially expanding its therapeutic scope. Its proprietary delivery technology allows engineered microbes to penetrate the skin barrier and produce therapeutic proteins in situ, addressing a key challenge in dermatology. Strategic academic partnerships with leading institutions further bolster its research capabilities. These factors collectively create barriers to entry and position Azitra uniquely in the precision dermatology space.

• Clinical and Regulatory Risk: Azitra’s lead product candidates are in early clinical stages, and there is uncertainty regarding their safety, efficacy, and regulatory approval outcomes.
• Financial Risk: The company has reported net losses and holds limited cash reserves, which may require additional financing to sustain operations and advance clinical programs.
• Listing Compliance Risk: Azitra has received NYSE American deficiency notices related to minimum stockholders’ equity and must comply with a plan through April 2027 to avoid delisting, which could impact stock liquidity and capital raising.
• Scientific and Technical Risk: Genetic engineering of bacteria and delivery of therapeutic proteins through the skin barrier involve complex scientific challenges that may affect product development timelines and success.
• Market and Competitive Risk: The company faces competition from established biotech and dermatology firms, and market acceptance of live biotherapeutic products remains uncertain.

• Azitra, Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology using engineered proteins and topical live biotherapeutic products [S1].
• The company has built a proprietary microbial library of approximately 1,500 unique bacterial strains, including over 900 unique strains of Staphylococcus epidermidis, which are screened for therapeutic characteristics [S1].
• Azitra’s platform is augmented by artificial intelligence and machine learning technology to analyze and predict drug-like molecules from its microbial library [S1].
• The company holds an exclusive worldwide license from Fred Hutchinson Cancer Center for SyMPL technology, enabling genetic engineering of previously intractable bacterial strains [S1].
• Azitra’s lead product candidates include ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and ATR-01 for ichthyosis vulgaris [S1].
• ATR-12 is in Phase 1b/2a clinical trial; first patient dosed in August 2024; initial safety results reported in first half of 2025 [S1].
• ATR-04 received FDA Fast Track designation in September 2024; Phase 1/2 trial initiated with first patient dosed in Q3 2025 [S1][N4].
• ATR-01 completed lead optimization in 2025 and is undergoing IND-enabling studies in 2026 [S1].
• Azitra has partnerships with Carnegie Mellon University, Fred Hutchinson Cancer Center, Yale University, Duke University, and others to support its platform and pipeline [S1].
• The company’s delivery technology enables genetically engineered microbes to penetrate the skin barrier and produce therapeutic proteins in deeper skin layers [S1].
• Azitra has not commenced commercial operations and reported zero revenue for fiscal year 2025 [S2].
• As of June 30, 2026, Azitra had cash and equivalents of approximately $6.7 million and current assets of $7.4 million, with current liabilities of $1.5 million, resulting in a current ratio of 4.86 and cash ratio of 4.4 [S2].
• Net loss for the quarter ended June 30, 2026 was approximately $3.3 million, with basic and diluted EPS of -$0.17 [S2].
• The company received NYSE American listing compliance notices in October 2025 and March 2026 related to minimum stockholders’ equity requirements and has a plan period through April 1, 2027 to regain compliance [N3][S2].
• Azitra completed a private placement in March 2026 to advance new cosmetic protein and peptide programs [N2].
• The company priced an underwritten public offering of 16.67 million shares at $0.30 per share in February 2024 [N6].
• Travis Whitfill was named COO in July 2023 [N7].